Mesoblast Limited
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Silviu Itescu
- Full Time Employees
- 108
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Collins Street Melbourne VIC Australia 3000
- IPO Date
- Jan 20, 2010
- CIK
- 0001345099
- Website
- mesoblast.com
- Similar Companies
- Business
- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), a commercial-stage regenerative medicine company founded in 2004 and headquartered in Melbourne, Australia, develops and commercializes allogeneic cellular medicines derived from its proprietary mesenchymal lineage cell technology platform to treat complex inflammatory diseases with significant unmet needs; its lead products include Ryoncil (remestemcel-L), the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged two months and older, Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 and biologic-resistant inflammatory bowel disease, Revascor (rexlemestrocel-L or MPC-150-IM) for advanced chronic heart failure, MPC-06-ID for chronic low back pain due to degenerative disc disease, MPC-25-IC for ischemic stroke, and an emerging pipeline of next-generation stromal cell therapies. The company operates manufacturing facilities for industrial-scale production of off-the-shelf cells sourced from healthy adult bone marrow donors, conducts late-stage clinical trials across cardiovascular, orthopedic, hematologic, and respiratory indications, and maintains subsidiaries and commercial partnerships in the United States, Australia, Singapore, Japan, Europe, and China with licensees including JCR Pharmaceuticals, Tasly Pharmaceutical Group, and Grünenthal for regional distribution and development. Recent developments include FDA approval of Ryoncil in early 2025 followed by its successful U.S. commercial launch generating $11.3 million in net product sales through June 2025 with biologic exclusivity until December 2036, addition to the S&P/ASX 200 Index in March 2025, a July 2025 Type B meeting with the FDA to plan a pivotal trial in adults with SR-aGVHD conducted via the NIH-funded bone marrow transplant network, ongoing Phase 3 trials for Revascor in heart failure and MPC-06-ID in back pain, strategic alliances such as the 2022 global partnership with Novartis for MSC-100-IV inflammatory therapies, and a strengthened balance sheet with $161.6 million in cash reserves supporting pipeline expansion despite a $102.1 million FY2025 net loss from R&D investments, commercial buildup, and refinancing activities.
Company News
Mesoblast (NASDAQ:MESO) Share Price Passes Above 50 Day Moving Average – Time to Sell?
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast H2 Earnings Call Highlights
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
First Look: JPM beats, RVMD surges, NXST-TGNA paused
Gregory George Acquires 1,981,890 Shares of Mesoblast (NASDAQ:MESO) Stock